Flagstar Bank NA vs Eli Lilly And Co — how do they compare? Flagstar Bank NA trades at $14.23 (market cap $5.82B), while Eli Lilly And Co trades at $1,213.76 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 189× Flagstar Bank NA's market cap, and Eli Lilly And Co pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| FLG | LLY | |
|---|---|---|
Market Cap | $5.82B | $1.10T |
Sector | Financials | Health |
52-Week High | $15.36 | $1.24K |
52-Week Low | $10.72 | $639.43 |
Dividend Yield | 0.29% | 0.56% |
Enterprise Value | — | $1.14T |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.
The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →